13.2 C
New York
Wednesday, May 25, 2022

Corbus Pharmaceuticals Holdings Inc (CRBP) stock is up in the after-hours. Here’s why

Corbus Pharmaceuticals Holdings Inc (CRBP) stock closed the recent trading session at $0.5, gaining 5.15% from the previous trading session. CRBP stock followed a bullish trend in the regular trading session as well in the after-market. On the last check, CRBP stock stayed in the green and further gained 16% to $0.58 during the after-hours. There is no recent news available from the company. Earlier this month, the company released the fiscal performance for the last quarter and fiscal year 2021. CRBP also took part in the 32nd Oppenheimer seminar. Moreover, the company was also featured by Zacks.com on 18 March 2022.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Corbus Pharmaceuticals Holdings Inc (CRBP) is a stage 3 clinical drug organization centered around the turn of events and commercialization of novel therapeutics to treat rare, constant, and genuine provocative and fibrotic infections. The company has a market capitalization of $62.62 million. CRBP has its base in Norwood, Massachusetts, USA.

CRBP Financials

Corbus Pharmaceuticals Holdings Inc (CRBP) released the fiscal performance for the last quarter and fiscal year 2021. The main points of the earnings are

  • CRBP reported revenue of $0 in the last quarter of FY21 versus $0.65 million in the same period of last year. Also, the sales in FY21 were reported to be $0.88 million as compared to $3.9 million in the previous year.
  • The company had a total loss of $10.2 million in Q4 of the fiscal year 2021 against the total loss of $8.6 million in the corresponding period of FY20. Further, the total loss in FY21 was reported to be $45.6 million versus $111.2 million in FY20.
  • Besides, CRBP had a loss of $0.08 and $0.37 per stock in Q4 and FY2021, respectively.

Company News

On 11 March 2022, CRBP declared to have taken part in the 32nd Oppenheimer healthcare seminar. The CEO of Corbus Pharmaceuticals, Yuval Cohen, took part in the discussion at the seminar. The seminar was held on 17 March 2022. The administration of CRBP also took part in virtual one-on-one gatherings with qualified individuals from the investment community.

CRBP was also featured by Zacks.com on 18 March 2022. The company holds a Zack Rank #2.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles